PATENT CLAIM ANALYSIS

Application Number: 16009613
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "449000"]

Abstract:
Transdermal therapeutic systems are described which have at least one electronic component, as well as methods for producing this type of transdermal therapeutic systems.

Claim (Index 7):
The transdermal therapeutic system according to  claim 1 ;\n wherein the at least one active agent is selected from the group of active agents consisting of anticholinergics, parasympatholytics, antimycotics, MAO-B inhibitors, serotonin antagonists, alpha2-receptor agonist, photosensitizers, hormones and proteins, preferably from the group of active agents consisting of 5-aminolevulinic acid, buprenorphine, capsaicin, clonidine, fentanyl, granisetron, glyceryl trinitrate, hydromorphone, memantine, oxybutynin, rivastigmine, rotigotine, selegiline, and sertaconazole.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 94.0
- Lexical Diversity: 1.13043
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['11793983', '13405689', '14506105', '14090079', '10497577']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7418115307939362
- 35 USC 102 Novelty (BERT): 0.4423458580992797
- Combined Prediction Score: 0.7118649635244706
- Mean Citation Score: 119.862586
- Max Citation Score: 121.27271
- Similarity Product: 100.51941937659144

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test